ClinicalTrials.gg
CompletedNCT06887959Updated Dec 15, 2025

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

A Phase 4 interventional study of Suzetrigine in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.

Enrollment
9th of 10
47 · median 165
Started
2025
with 1 other
Phase 4
5 of 10
3 open now
Registered
5th of 10
by date
Lead sponsor
6 of 10
Vertex Pharmaceuticals Incorporated

Among the 10 studies testing suzetrigine in Acute Pain, this one is the 9th largest by enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 5th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing suzetrigine in Acute Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthroscopic orthopedic procedures.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
  • Scheduled to undergo a procedure that is in one of the following categories that would typically be treated with opioid therapy for at least 72 hours postoperatively such as

    • Laparoscopic intraperitoneal or retroperitoneal procedure
    • Arthroscopic orthopedic procedure

Key Exclusion Criteria:

-Participated in previous study with Suzetrigine or received Journavx

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Suzetrigine (SUZ)

    Participants will receive SUZ for 14 days or until their pain resolves, whichever occurs first.

    Drug: Suzetrigine

Interventions

  • Tablets for oral administration.

    Also known as: VX-548, SUZ, Journavx

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment

    Time frame: From Day 3 up to Day 14

07

Study locations

17 sites
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85260, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • MedStar
    Baltimore, Maryland 21218, United States
  • Oasis Clinical Research
    Las Vegas, Nevada 89121, United States
  • Cooper University HealthCare (CUH)
    Camden, New Jersey 08103, United States
  • North Shore University Hospital - Anesthesiology
    Manhasset, New York 11030, United States
  • OrthoCarolina - Hip & Knee Center
    Charlotte, North Carolina 28207, United States
  • Eximia Research-Durham
    Durham, North Carolina 27704, United States
  • Duke University Hospital - Anesthesiology
    Durham, North Carolina 27710, United States
  • West Clinical Research
    Morehead City, North Carolina 28557, United States
  • Seaside Clinical Research Institute
    Wilmington, North Carolina 28412, United States
  • UH Cleveland Medical Center - Anesthesiology
    Cleveland, Ohio 44106, United States
  • University of Tennessee Medical Center - Anethesiology
    Knoxville, Tennessee 37920, United States
  • HD Research LLC | First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Memorial Hermann Village
    Houston, Texas 77043, United States
  • Tidewater Clinical Research
    Norfolk, Virginia 23502, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Oct 2025, 7 months.

Of 84 phase 4 interventional studies under Acute Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 21, 2025
StartActual
Mar 27, 2025
Primary completionActual
Oct 27, 2025
CompletionActual
Nov 10, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06887959
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Mar 27, 2025
Primary completion
Oct 27, 2025
Completion
Nov 10, 2025
Last update
Dec 15, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion